BONESUPPORT Holding AB (publ) – Publishes Q1 2022 interim report
Published: 2022-05-04
BONESUPPORT Holding AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2022.
STRONG SALES GROWTH
JANUARY – MARCH 2022
- Net sales increased by 48 percent (36 percent at constant exchange rates) and amounted to SEK 66.3 million (44.8).
- The North America (NA) segment reported a sales increase of 64 percent (47 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales increase of 28 percent (22 percent at constant exchange rates).
- The gross margin amounted to 90.5 percent (88.6) with a positive mix effect from increased sales in North America.
- Operating result amounted to SEK -16.5 million (-19.7).
- Earnings per share, before and after dilution, were SEK -0.25 (-0.32).
“U.S. sales grew with 64 percent in the quarter.” Emil Billbäck, CEO
EVENTS DURING THE REPORTING PERIOD
- In January 2022, the company announced that a distribution agreement had been signed with OrthoPediatrics Corp, a leading company in the orthopedic pediatric market. The distribution partnership expands BONESUPPORT’s market access further as it gives CERAMENT BVF access to OrthoPediatrics’ network of 250 children’s hospitals. Sales for the period included a first order from OrthoPediatrics, which amounted to SEK 2.6 million.
EVENTS AFTER THE REPORTING PERIOD
- CMS, Centers for Medicare & Medicaid Services, communicated in end of April a favorable NTAP, New Technology Add-On Payments, ruling for CERAMENT G at USD 4 920, conditioned a regulatory approval before July 1 this year.
For more information contact:
BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com
Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se
This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-05-04 08:00 CEST.
About BONESUPPORT™
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
Attachments
Source: BONESUPPORT
